Artificial Intelligence-guided Precision Treatment of High-grade Serous Ovarian Carcinoma

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-80
SponsorThe Affiliated Hospital of Qingdao University

About this trial

The subjects of this study are patients with high-grade serous ovarian cancer who have undergone surgical resection. The aim is to construct an artificial intelligence model for predicting postoperative recurrence, metastasis and overall survival of patients based on multimodal data such as surgical pathological images (HE images and IHC images of immune microenvironment-related markers), preoperative baseline imaging data and detailed clinical information of patients. In addition, multi-omics sequencing analysis will be used to deeply explore the heterogeneity of the tumor microenvironment, with the expectation of quantifying the postoperative recurrence risk of patients with high-grade serous ovarian cancer and providing new ideas for the precise diagnosis and treatment of patients with high-grade serous ovarian cancer.

Eligibility criteria

Qualifiers

Histologically confirmed high-grade serous ovarian carcinoma using resection specimens.

Well-preserved surgical paraffin-embedded tumor specimens.

Complete clinical information and survival follow-up data.

Disqualifiers

Received preoperative neoadjuvant treatment.

Poor preservation of surgical paraffin specimens.

Incomplete clinical information and survival follow-up data.

With concurrent malignancies other than high-grade serous ovarian carcinoma.

Trial design

Treatments tested in this trial

  • No Intervention: Observational Cohort

Treatment groups

1,300 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

The Affiliated Hospital of Qingdao University

Lead sponsor

Shandong Provincial Hospital

Collaborator

Yantai Yuhuangding Hospital

Collaborator

Peking University Third Hospital

Collaborator